Nippon Shinyaku Co., Ltd. (TYO: 4516)
Japan
· Delayed Price · Currency is JPY
3,737.00
+30.00 (0.81%)
Jan 20, 2025, 3:30 PM JST
Nippon Shinyaku Revenue
Nippon Shinyaku had revenue of 40.20B JPY in the quarter ending September 30, 2024, with 10.74% growth. This brings the company's revenue in the last twelve months to 154.27B, up 5.41% year-over-year. In the fiscal year ending March 31, 2024, Nippon Shinyaku had annual revenue of 148.26B with 2.83% growth.
Revenue (ttm)
154.27B
Revenue Growth
+5.41%
P/S Ratio
1.63
Revenue / Employee
69.71M
Employees
2,213
Market Cap
251.79B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2024 | 148.26B | 4.08B | 2.83% |
Mar 31, 2023 | 144.18B | 6.69B | 4.87% |
Mar 31, 2022 | 137.48B | 15.60B | 12.80% |
Mar 31, 2021 | 121.89B | 5.25B | 4.50% |
Mar 31, 2020 | 116.64B | 1.92B | 1.67% |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Chugai Pharmaceutical | 1,142.35B |
Daiichi Sankyo Company | 1,758.07B |
HOYA Corporation | 812.74B |
Takeda Pharmaceutical Company | 4,546.08B |
Otsuka Holdings | 2,269.56B |
Terumo | 986.67B |
Astellas Pharma | 1,772.16B |
Olympus | 973.60B |
Nippon Shinyaku News
- 4 days ago - Regenxbio Secures A Partnership With Nippon Shinyaku For RGX-111 & 121 - Seeking Alpha
- 6 days ago - REGENXBIO partners with Nippon Shinyaku for MPS therapies - Seeking Alpha
- 6 days ago - Why KB Home Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket - Benzinga
- 4 months ago - Week In Review: Nippon Shinyaku Signs $735m Deal For DMD Therapy - Seeking Alpha
- 4 months ago - Capricor Therapeutics partners with Nippon Shinyaku for European commercialization of Deramiocel - Seeking Alpha
- 4 months ago - EXCLUSIVE: Capricor Therapeutics Inks European Expansion, Commercialization Pact For Lead Asset With Japanese Pharma Firm - Benzinga